- Allergan's Botox approved for upper limb spasticity
- FDA staff questions efficacy of Medtronic's device for treating epilepsy
- FDA finds no fracture risk with bisphosphonates
- Cangene, Baxter add boxed warning to WinRho SDF for immune thrombocytopenic purpura indication
- Cytokinetics' CK-2017357 granted orphan drug status for ALS
- Private FFS MA plans may be linked with higher costs for beneficiaries, GAO report shows
- Pediatric subspecialty telephone consultations may be cost-saving for Medicaid, research reveals
- Use of mental health services greater in health plans with parity in cost sharing, data find
- Public opinions appear split on health care affordability, satisfaction, survey finds
- In Brief: California Supreme Court
Home :: Cardiology :: Cardiology Conferences
American Heart Association Scientific Sessions 2008
November 8 - 12, 2008 New Orleans, LA- Study identifies potential predictors of diabetes among patients with high CVD risk
- Irbesartan does not seem to reduce death, hospitalization in patients with preserved LVEF HF, study finds
- Improving bystander intervention, postresuscitation care, other strategies necessary to increase survival after cardiac arrest
- Oral anticoagulant rivaroxaban meets secondary, not primary, efficacy endpoint in dose-finding study, will advance to Phase III trial
- Better efficacy, safety demonstrated by atorvastatin, fenofibrate fixed-dose combination relative to monotherapies
ACC's 57th Annual Scientific Session
March 29 - April 1 2008 Chicago, IL- Experts discuss ENHANCE trial data, implications for clinical practice
- Celecoxib increases cardiovascular risk in dose-, regimen-related fashion
- Pioglitazone prevents progression of coronary atherosclerosis in patients with CAD, diabetes
- STRADIVARIUS trial fails to show effect of rimonabant in primary IVUS endpoint, but secondary endpoint data suggest drug might reduce atherosclerosis progression
- Cardiac resynchronization therapy might benefit asymptomatic, mildly symptomatic patients with HF, according to 12-month REVERSE trial data
- Radiotherapy, chemotherapy increase risks of second malignancy, cardiovascular disease similar to smoking in patients with testicular cancer, researchers report
- High levels of hemoglobin A1C appear to increase risk of complications following CABG
- Telmisartan as effective as ramipril, better tolerated
- Pioglitazone prevents progression of coronary atherosclerosis in patients with CAD, diabetes
- Drugs that lower BP reduce cardiovascular morbidity, mortality in patients undergoing dialysis, meta-analysis finds
- Radiotherapy, chemotherapy increase risks of second malignancy, cardiovascular disease similar to smoking in patients with testicular cancer, researchers report
- Infliximab infusion may increase risk of ventricular arrhythmias in patients with RA, data suggest
- Lipid-modifying drugs may decrease all-cause, cardiovascular-specific mortality in patients on peritoneal dialysis, study data suggest
- Preeclampsia associated with epilepsy in offspring, data show
- Experts discuss ENHANCE trial data, implications for clinical practice
